Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Estradiol

A list of these Estradiol articles makes it easy for you to quickly access relevant information. We have prepared the following professional Estradiol, hoping to help solve your questions and better understand the product information you care about.
  • Drug Patent & Exclusivity Expiration Report - Week of Aug 04 2025

    Drug Patent & Exclusivity Expiration Report - Week of Aug 04 2025

    2025-08-04

    This week, there are 9 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUMITOMO PHARMA SWITZERLAND GMBH's MYFEMBREE, containing active ingredient ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - BAYER HEALTHCARE PHARMACEUTICALS INC's NUBEQA, containing active ingredient DAROLUTAMIDE - BAYER HEALTHCARE PHARMACEUTICALS INC's LAMPIT, containing active ingredient NIFURTIMOX - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - GENENTECH INC's EVRYSDI, containing active ingredient RISDIPLAM - ALNYLAM PHARMACEUTICALS INC's ONPATTRO, containing active ingredient PATISIRAN SODIUM - AMICUS THERAPEUTICS US LLC's GALAFOLD, containing active ingredient MIGALASTAT HYDROCHLORIDE Read More